Novorapid Flexpen Novo Nordisk — Research Summary
Novorapid Flexpen is a rapid-acting insulin aspart formulation developed by Novo Nordisk for diabetes research applications. This biosynthetic insulin analogue features a modified amino acid sequence where proline at position B28 is replaced with aspartic acid, creating accelerated absorption kinetics compared to regular human insulin. Researchers examining glucose homeostasis mechanisms rely on insulin aspart’s predictable pharmacokinetic profile in laboratory investigations. The FlexPen delivery system provides precise dosing capabilities essential for controlled experimental protocols. Investigators studying metabolic pathways can examine how this rapid-acting formulation affects cellular glucose uptake and glycogen synthesis processes.
Laboratory Applications
Research teams utilise Novorapid Flexpen to investigate postprandial glucose regulation in various experimental models. The compound’s rapid onset characteristics make it valuable for studying acute insulin response mechanisms and glucose homeostasis. Laboratory studies examine how insulin aspart interacts with glucose transport proteins and influences hepatic glucose production. Metabolic researchers analyse the relationship between insulin timing and glycemic excursions in controlled settings. Scientists investigating diabetes pathophysiology use this formulation to study insulin resistance mechanisms and pancreatic beta-cell function. The compound serves as a reference standard when comparing novel insulin analogues or examining insulin signalling pathways. Research facilities studying endocrinology benefit from Stroid UK Shop comprehensive range of insulin research compounds, alongside selective androgen receptor modulators and peptide research materials.
Technical Specifications
| Active Ingredient | Insulin aspart |
|---|---|
| Concentration | 100 units/mL |
| Delivery System | FlexPen pre-filled |
| Volume | 3mL cartridge |
| Manufacturer | Novo Nordisk |
| Storage | 2-8°C refrigerated |
| Onset Profile | Rapid-acting |
| Formulation | Clear solution |
Each FlexPen contains insulin aspart in a sterile, isotonic solution with glycerol, phenol, metacresol, zinc chloride, disodium hydrogen phosphate, and sodium chloride. The pH is adjusted with hydrochloric acid or sodium hydroxide to maintain stability throughout the research period.
Research Compliance
Novorapid Flexpen is supplied exclusively for in-vitro research purposes and laboratory investigations into glucose metabolism and insulin signalling pathways. This product is not intended for human consumption or therapeutic application. Researchers must ensure proper storage conditions and handling protocols are maintained throughout experimental procedures. All studies should be conducted in accordance with institutional guidelines for insulin research and laboratory safety standards.
